смотреть онлайн фильм с участием натальей антоновой
Главное меню:
Интересное
смотреть онлайн фильм с участием натальей антоновой, S3 Episode 5: Important Advances in Small Cell Lung Cancer, Zenocutuzumab Effective Against NRG1 Fusion Cancers - Medscape, Changes in the Treatment Landscape of Early-Stage Non–Small Cell Lung , Potential Drivers of LCINS - Medscape, Evaluation and Management of Small Pulmonary Nodules - Page 3 - Medscape, Early Detection and Screening of Lung Cancer - Page 2 - Medscape, The Landscape of EGFR Pathways and Personalized Management of Non-small .
Borghaei: I'd be happy to. I am an investigator on the tarlatamab study, from phase 1 onward, so I do think that the drug is an interesting addition — once approved, of course; it is still under investigation. It should be considered investigational when used in the clinical trial setting. This is a drug that I've had a lot of interest in just because of its bispecific nature. By definition, these are bispecific T-cell engagers, as the name suggests and as you said, so one arm of the drug directly engages the CD3, and the other arm of the study obviously goes after a tumor antigen — in this case, DLL3. Many of the listeners are familiar with the fact that DLL3 has been around for a while. We've had other drugs targeting DLL3 in the past, some with success and some without. The target is a relevant target in the world of small cell lung cancer, based on a lot of the preclinical work in some clinical trials. You can think of bispecific T-cell engagers as bringing the immune system and the tumor in close proximity and generating what we used to call in the old days an immunologic synapse, so to speak. The idea here was that with the two arms, you can sort of bring the whole immune component into the tumor microenvironment, hoping for a better immune response. The examined two different doses of this drug. Both doses come from the phase 1, like in any other study. But on the phase 1 clinical trial, a multitude of doses were investigated in multiple cohorts, going all the way to a 100-mg dose. The question here was, what was the clinical efficacy of the higher dose vs the lower dose? Having treated a number of patients at our institutions on this trial, I have to say that I've been very happy with the responses. And again, as you correctly pointed out, the durability, because we get a lot of drugs in the world of small cell lung cancer where you might have an initial response but unfortunately the durability isn't there. At least so far, there were with the two doses of the drug. We're beginning to have a relatively healthy dataset of patients in terms of clinical data and toxicity. The response rate of 40% with a 10-mg dose is very interesting, considering that these patients were pretreated. In the phase 1 trial, the response rates were a little bit lower. About 30% of patients on the phase 1 had multiple lines of prior therapy, some of them beyond three lines of treatment, which is a unique situation in small cell lung cancer. I don't know how you think about this, but yes, they're heavily pretreated, but it's also a rare patient population with small cell lung cancer that can go three lines of treatment and beyond and still have a good-enough performance status and other factors that we require for participation in a clinical trial. In the world of small cell lung cancer, I think we have to be careful what we're talking about when we say "a lot of third-line–and–beyond patients." It still matters, but nonetheless, the drug does show decent durability as a single agent, and interesting enough, the OS as reported — obviously, additional work is needed., Drs Jacob Sands and Hossein Borghaei discuss small cell lung cancer, including breakthroughs and challenges in immunotherapy., The bispecific antibody shows particularly promising results in non–small cell lung cancer (NSCLC) and pancreatic cancer patients, with responses lasting a median of 11.1 months..
Narjust Florez, MD, reflects on the significant changes in the treatment landscape of early-stage non-small cell lung cancer in recent years., An American Cancer Society expert urges clinicians to advocate for action in the healthcare industry to help combat climate change and its effects on lung cancer incidence., Common benign etiologies of lung nodules with an air bronchogram include pulmonary lymphoma, sarcoidosis and round pneumonia. [35, 55, 56] Cavitation can be present in both benign and malignant , The rationale for developing effective lung cancer screening stems from the fact that lung cancer causes 1.3 million deaths worldwide each year and accounts for more cancer deaths than breast , The -216T allele is preferentially amplified in human lung cancer specimens and cancer cell lines., Among patients with resected non-small-cell lung carcinoma, tumors over 15 mm in diameter are associated with an increased risk for metastases and shorter survival..